Haemophilias A and B. (Q35143113)

6 August 2017

1 reference

title

Haemophilias A and B. (English)

1 reference

6 August 2017

0 references

Paula H B Bolton-Maggs

series ordinal

1

1 reference

PubMed ID

12781551

6 August 2017

K John Pasi

series ordinal

2

1 reference

PubMed ID

12781551

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

361

1 reference

6 August 2017

9371

1 reference

6 August 2017

1801-1809

1 reference

Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Rare coagulation deficiencies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Modifier genes in haemophilia: their expansion in the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Isolation and characterization of a cDNA coding for human factor IX

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Characterization of the human factor VIII gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The molecular basis of haemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Perinatal management of newborns with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Factor concentrate prophylaxis for neonates with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Normal vaginal delivery is to be recommended for haemophilia carrier gravidae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

von Willebrand disease: still an intriguing disorder in the era of molecular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Common orthopaedic problems in haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Experience of prophylaxis treatment in children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The impact of prophyactic treatment on children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Implanted vascular access devices (ports) in children: complications and their prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The use of central venous catheters (portacaths) in children with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

A prospective clinical trial of implantable central venous access in children with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Complications experienced with central venous catheters in children with congenital bleeding disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Asymptomatic liver disease in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

A clinicopathological study of liver disease in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Progressive liver disease in haemophilia: an understated problem?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The natural history of chronic hepatitis C in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The natural history and antiviral treatment of hepatitis C in haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Outcome of orthotopic liver transplantation in patients with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Haemophilia 2002: emerging risks of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Protease inhibitor therapy and bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Treatment of haemophilia in the United Kingdom 1981-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Inhibitors in congenital haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Inhibitors: resolving diagnostic and therapeutic dilemmas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

NovoSeven in immune tolerance therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Tolerance induction using the Malmö treatment model 1982-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Inhibitors in young boys with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Management of haemophilia B patients with inhibitors and anaphylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Gene therapy for haemophilia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

Gene therapy ethics and haemophilia: an inevitable therapeutic future?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993–2003

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913405-8

7 January 2021

10.1016/S0140-6736(03)13405-8

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12781551